Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Apyx Medical Corp (APYX)

Apyx Medical Publishes Renuvion Study Showing Elastin and Inflammation Changes

Neutral Impact 2 of 5 other Written later

Apyx Medical announced on September 29, 2026 that a prospective clinical study of its Renuvion technology was published in Plastic and Reconstructive Surgery — Global Open. The filing contains no financial results, guidance, or changes to the company's business, and the study covered seven patients, with six completing the Day 180 visit.

Key points

  • Day 180 results (n=6) showed a 30% increase in elastin fiber density and a 34% reduction in inflammation versus untreated control tissue.
  • Seven patients undergoing lower rhytidectomy (facelift) were enrolled at two U.S. investigational sites; six completed the Day 180 visit.
  • The study was published in Plastic and Reconstructive Surgery — Global Open, and the press release is filed as Exhibit 99.1.

The filing

CompanyApyx Medical Corp (APYX)
Form8-K, current report
Filed with the SECSep 29, 2026, 4:19 PM ET
Accession number0001437749-26-031468

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.